71 related articles for article (PubMed ID: 12051746)
21. Effect of pyrroloquinoline quinone (PQQ) on melanogenic protein expression in murine B16 melanoma.
Sato K; Toriyama M
J Dermatol Sci; 2009 Feb; 53(2):140-5. PubMed ID: 19013771
[TBL] [Abstract][Full Text] [Related]
22. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
Ranes MK; El-Abbadi M; Manfredi MG; Mukherjee P; Platt FM; Seyfried TN
Br J Cancer; 2001 Apr; 84(8):1107-14. PubMed ID: 11308262
[TBL] [Abstract][Full Text] [Related]
23. TXM13 human melanoma cells: a novel source for the inhibition kinetics of human tyrosinase and for screening whitening agents.
Park YD; Kim SY; Lyou YJ; Lee DY; Yang JM
Biochem Cell Biol; 2006 Feb; 84(1):112-6. PubMed ID: 16462895
[TBL] [Abstract][Full Text] [Related]
24. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway.
Halaban R; Patton RS; Cheng E; Svedine S; Trombetta ES; Wahl ML; Ariyan S; Hebert DN
J Biol Chem; 2002 Apr; 277(17):14821-8. PubMed ID: 11812790
[TBL] [Abstract][Full Text] [Related]
25. A potent tyrosinase activator from Radix Polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells.
Guan S; Su W; Wang N; Li P; Wang Y
Phytother Res; 2008 May; 22(5):660-3. PubMed ID: 18389468
[TBL] [Abstract][Full Text] [Related]
26. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
27. pH-sensitive liposomes--principle and application in cancer therapy.
Karanth H; Murthy RS
J Pharm Pharmacol; 2007 Apr; 59(4):469-83. PubMed ID: 17430630
[TBL] [Abstract][Full Text] [Related]
28. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity.
Morilla MJ; Montanari J; Frank F; Malchiodi E; Corral R; Petray P; Romero EL
J Control Release; 2005 Apr; 103(3):599-607. PubMed ID: 15820407
[TBL] [Abstract][Full Text] [Related]
29. 2, 3, 5, 4'-tetrahydroxystilbene-2-O-beta-D-glucoside (THSG) induces melanogenesis in B16 cells by MAP kinase activation and tyrosinase upregulation.
Jiang Z; Xu J; Long M; Tu Z; Yang G; He G
Life Sci; 2009 Aug; 85(9-10):345-50. PubMed ID: 19527735
[TBL] [Abstract][Full Text] [Related]
30. N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
Yamazaki Y; Kawano Y; Yamanaka A; Maruyama S
Bioorg Med Chem Lett; 2009 Aug; 19(15):4178-82. PubMed ID: 19524439
[TBL] [Abstract][Full Text] [Related]
31. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
32. Inhibitory effects of arbutin on melanin biosynthesis of alpha-melanocyte stimulating hormone-induced hyperpigmentation in cultured brownish guinea pig skin tissues.
Lim YJ; Lee EH; Kang TH; Ha SK; Oh MS; Kim SM; Yoon TJ; Kang C; Park JH; Kim SY
Arch Pharm Res; 2009 Mar; 32(3):367-73. PubMed ID: 19387580
[TBL] [Abstract][Full Text] [Related]
33. N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset.
Guerrera M; Ladisch S
Cancer Lett; 2003 Nov; 201(1):31-40. PubMed ID: 14580684
[TBL] [Abstract][Full Text] [Related]
34. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
35. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD
Biochem J; 2004 Aug; 381(Pt 3):861-6. PubMed ID: 15128268
[TBL] [Abstract][Full Text] [Related]
36. Tyrosinase and glycoprotein folding: roles of chaperones that recognize glycans.
Petrescu SM; Branza-Nichita N; Negroiu G; Petrescu AJ; Dwek RA
Biochemistry; 2000 May; 39(18):5229-37. PubMed ID: 10819991
[No Abstract] [Full Text] [Related]
37. 3-hydroxycoumarin loaded vesicles for recombinant human tyrosinase inhibition in topical applications.
Schlich M; Fornasier M; Nieddu M; Sinico C; Murgia S; Rescigno A
Colloids Surf B Biointerfaces; 2018 Nov; 171():675-681. PubMed ID: 30107341
[TBL] [Abstract][Full Text] [Related]
38. Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine.
Halaban R; Cheng E; Svedine S; Aron R; Hebert DN
J Biol Chem; 2001 Apr; 276(15):11933-8. PubMed ID: 11124258
[TBL] [Abstract][Full Text] [Related]
39. Synthetic 1-deoxynojirimycin N-substituted peptides offer prolonged disruption to N-linked glycan processing.
Aguilar AL; Escribano J; Wentworth P; Butters TD
ChemMedChem; 2014 Dec; 9(12):2809-13. PubMed ID: 25352425
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM
Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
